香港大学研究人员宣布开发出全球首款鼻喷剂，可将神经治疗粉末直接送达大脑，为缺血性中风患者提供急救。 该名为NanoPowder的药物旨在将脑损伤减少80%以上，并提高中风存活率。 临床试验预计于2030年前进行。
香港大学（HKU）李嘉诚医学院及先进生物医学仪器中心的研究团队开发了这一创新药物NanoPowder。该鼻喷剂利用“nano-in-micron”技术绕过血脑屏障，通过鼻腔直达大脑途径将药物送至目标区域，无需手术或注射。
“我们使用‘nano-in-micron’技术绕过血脑屏障，这是一种通常阻挡大多数药物进入大脑的天然屏障，”领衔研究团队的药理学及药剂学系教授周承芳（Aviva Chow Shing-fung）表示。“通过鼻-脑途径，该治疗将药物直接送达目标区域，免除手术或注射的需要。”
该治疗最初供护理人员使用，随后扩展至护理设施的高风险群体，并最终通过药房向公众开放。 该创新在今年第51届日内瓦国际发明展上荣获特别大奖及金牌。
Researchers at Texas A&M University have developed a nasal spray that appears to reverse aspects of brain aging after just two doses. The treatment reduced inflammation and restored memory function in models for months afterward. The findings were published in the Journal of Extracellular Vesicles.
由 AI 报道 事实核查
Researchers from the Institute for Bioengineering of Catalonia and collaborating institutions report that engineered “supramolecular” nanoparticles restored aspects of blood-brain barrier function in Alzheimer’s-model mice, rapidly lowering brain amyloid-β and producing improvements on behavioral and memory tests.
A copper-based drug has shown potential to reduce toxic protein buildup and improve memory in laboratory models of Alzheimer’s disease. Researchers at Monash University found that the compound Cu(ATSM) enhanced the brain’s waste-clearing mechanisms. The results were published in ACS Chemical Neuroscience.
由 AI 报道
A widely studied anti-aging treatment triggered significant brain damage in mice, according to new research from the University of Connecticut. The drug combination dasatinib plus quercetin caused myelin loss and changes resembling those seen in multiple sclerosis. The findings raise questions about its use in longevity studies and off-label therapies.